AMBS has cornered the AD Diagnostic Market! Wi
Post# of 30028
With the purchase of the 2 Georgetown blood tests, combined with Lympro, AMBS has essentially cornered the market. The 3 types of blood tests we now control represent all there really is in the AD diagnostic blood test space.
1) LymPro's "cell cycle" test,
2) Georgetown's "exosomes" test, and
3) Georgetown's "plasma lipids" test.
These three tests are all very different approaches to diagnosing alzheimers. But now AMBS controls all three! If we perform all 3 blood tests and a patient tests positive, the accuracy will be sky high because of the 3 completely different approaches used!! This is huge! We may even replace the need for clinical trials to use Amivid if our 3 tests combined are far more accurate and less invasive!
Literally, we have become the world's premiere AD diagnostic company. Our value went up huge today. Maybe some of the idiots bashing Gerald don't understand the implications, but the market soon will. Georgetown's test has been publicized all over the media. I don't think we've even begun to wrap our minds around the significance of the deal that was finalized today!!